List of Excipients in Branded Drug GOOD NEIGHBOR PHARMACY CLEARLAX

Generic Drugs Containing GOOD NEIGHBOR PHARMACY CLEARLAX

Company	Ingredient	NDC	Excipient
Amerisource Bergen	polyethylene glycol 3350	46122-805	SUCRALOSE

What are the Most Frequently-Used Excipients in GOOD NEIGHBOR PHARMACY CLEARLAX?

# Of NDCs	Excipient
1	SUCRALOSE

Good Neighbor Pharmacy ClearLax Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Good Neighbor Pharmacy ClearLax is an OTC polyethylene glycol 3350 laxative. Its core commercial advantage is a simple, low-cost powder formulation with no pharmacologically active ingredient beyond PEG 3350. The product has limited conventional patent protection, no biosimilar exposure, and no meaningful formulation barrier unless the manufacturer creates differentiated dosage forms, flavor systems, packaging, or combination products.

What is Good Neighbor Pharmacy ClearLax?

Good Neighbor Pharmacy ClearLax contains polyethylene glycol 3350, an osmotic laxative used for occasional constipation. The labeled adult dose is typically 17 grams dissolved in 4 to 8 ounces of beverage and taken once daily for up to seven days, subject to the applicable product labeling.[1]

Attribute	ClearLax profile
Brand	Good Neighbor Pharmacy ClearLax
Active ingredient	Polyethylene glycol 3350
Drug category	Osmotic laxative
Dosage form	Oral powder for solution
Primary use	Occasional constipation
Typical adult dose	17 g once daily
Route	Oral
Regulatory category	OTC laxative
Biological product status	Not applicable
Orange Book status	Generally not applicable to this OTC private-label product
Primary commercial channel	Community pharmacy and private-label retail

The product competes with MiraLAX, store-brand PEG 3350 products, lactulose, magnesium-based laxatives, stimulant laxatives, and fiber products.

What excipients does Good Neighbor Pharmacy ClearLax use?

The marketed powder has a minimal excipient profile. Public labeling for PEG 3350 powder products commonly identifies no inactive ingredients or uses only processing and packaging components that do not materially alter the drug product.[1]

This structure creates a low-cost formulation but limits differentiation. PEG 3350 is itself the therapeutic ingredient and provides the powder’s bulk, osmotic activity, and dissolution behavior. The principal product-development variables are therefore:

• Particle size and particle-size distribution
• Powder flow and dose uniformity
• Moisture control
• Dissolution speed
• Taste and mouthfeel
• Unit-dose or multidose packaging
• Flavoring and sweetening systems
• Compatibility with beverages
• Child-resistant and senior-friendly packaging

An excipient change can affect labeling, dissolution, stability, sensory properties, and manufacturing economics. A flavored version would require a new inactive-ingredient assessment and potentially updated labeling, stability data, and manufacturing controls.

How can excipients create commercial differentiation?

The strongest opportunity is not a new therapeutic mechanism. It is a better patient experience around an established active ingredient.

Flavor and palatability

Unflavored PEG 3350 is widely mixed with water, juice, coffee, tea, or other beverages. A manufacturer could develop lemon, berry, orange, or neutral-taste variants. Commercial value would depend on whether the flavor masks the powder’s mouthfeel without reducing beverage compatibility.

A flavored product could support:

• Premium pricing over unflavored store brands
• Pediatric or family positioning, subject to labeling requirements
• Subscription sales through e-commerce
• Brand differentiation in pharmacy planograms
• Private-label extensions for specific retail chains

The formulation must avoid excessive sweetness, sedimentation, clumping, or incompatibility with common beverages.

Sweetener systems

Low-calorie sweeteners, sugar, polyols, or natural flavor systems may improve consumer acceptance. Each option changes the regulatory and commercial profile.

Excipient strategy	Commercial benefit	Main risk
Sucralose or acesulfame potassium	Low-calorie sweetness	Aftertaste and consumer preference
Sugar	Familiar taste	Caloric content and diabetes positioning
Steviol glycosides	“Natural” positioning	Bitterness and variable taste profile
Polyols	Sweetness and mouthfeel	Gastrointestinal tolerance
Natural flavors	Premium positioning	Stability and supply-chain variability
Buffering agents	Taste and dissolution control	Label and compatibility complexity

For an occasional-use laxative, the excipient system should not introduce additional gastrointestinal discomfort. Polyols and poorly tolerated sweeteners could undermine the product’s intended benefit.

Effervescent or rapid-dissolution formats

A rapid-dissolution product could use acid-base excipients or engineered particles to disperse PEG 3350 faster. This would create a distinct dosage form, but the commercial case is less straightforward because the standard powder already dissolves in a beverage.

Potential benefits include:

• Faster preparation
• More consistent dispersion
• Single-serve portability
• Improved adherence for travelers and caregivers

The costs include greater moisture sensitivity, more complex packaging, possible taste problems, and additional stability work. The format would also need to preserve the labeled PEG 3350 dose.

Unit-dose sachets and stick packs

Packaging is likely to produce more practical value than a complex excipient reformulation. Single-dose sachets can improve convenience, dose control, portability, and pharmacy merchandising.

A unit-dose strategy can target:

• Travelers
• Assisted-living facilities
• Hospital discharge programs
• Mail-order pharmacy
• E-commerce bundles
• Employer and health-plan channels

The main risks are packaging cost, powder segregation, moisture ingress, and increased shipping volume.

What regulatory status applies to ClearLax?

PEG 3350 is recognized in the FDA OTC laxative framework. The applicable monograph provisions address the active ingredient, dose, labeling, and conditions for lawful marketing.[2]

A compliant unflavored PEG 3350 product generally has a simpler regulatory pathway than an NDA-based prescription product. The commercial owner still must control:

• Identity and quality of PEG 3350
• Assay and impurity specifications
• Microbial quality
• Moisture content
• Powder uniformity
• Container-closure integrity
• Stability
• Drug Facts labeling
• Manufacturing compliance

A new flavor or excipient system may remain within the OTC monograph pathway if it meets all applicable requirements. It does not automatically receive the same regulatory treatment as the existing unflavored product. The manufacturer must evaluate the ingredient’s permitted use, concentration, safety, labeling, and manufacturing controls.

What patents protect Good Neighbor Pharmacy ClearLax?

The core PEG 3350 product has limited practical patent protection. PEG 3350 is an established active ingredient used in multiple generic and private-label products. The principal competitive barriers are manufacturing quality, procurement, packaging, retail placement, and brand economics rather than blocking patents.

IP category	Relevance to ClearLax
PEG 3350 composition patent	Low practical relevance; established active ingredient
Core powder formulation patent	Limited unless a novel formulation is developed
Method-of-use patent	Limited for conventional occasional constipation use
Flavor formulation patent	Possible for a genuinely novel and non-obvious system
Sachet or packaging patent	Possible, but generally narrow
Manufacturing-process patent	Possible for particle engineering or blending processes
Trademark protection	Relevant to “ClearLax” and Good Neighbor Pharmacy branding
Trade secret protection	Relevant to supplier specifications, flavor systems, and process controls

A differentiated formulation could support patent filings around particle morphology, dissolution performance, moisture protection, taste masking, or a specific excipient combination. Such patents would be narrower than a composition patent and could be difficult to enforce if competing products achieve similar performance through different formulations.

When does ClearLax lose exclusivity?

ClearLax does not have a conventional prescription-drug exclusivity timeline. The product competes in the OTC market, where market exclusivity is driven by brand recognition, retail contracts, manufacturing scale, packaging, and consumer loyalty.

There is no apparent statutory exclusivity period comparable to a new chemical entity, orphan drug, or pediatric exclusivity period. The product can face substitution from other PEG 3350 products marketed under national brands, store brands, and pharmacy labels.

The practical exclusivity profile is:

Exclusivity driver	Expected strength
Regulatory exclusivity	Low
Core active-ingredient exclusivity	Low
Formulation exclusivity	Low for standard powder; potentially moderate for novel formats
Trademark exclusivity	Moderate within the relevant market
Retail distribution	Potentially high if supported by pharmacy contracts
Cost advantage	High for scaled private-label manufacturing
Consumer loyalty	Variable

Are there Paragraph IV challenges or Orange Book listings?

Paragraph IV litigation is generally associated with abbreviated new drug applications and Orange Book-listed patents for prescription and certain approved drug products. A private-label OTC PEG 3350 product is not ordinarily the type of product that generates a conventional Paragraph IV campaign.

The relevant competitive risks are instead:

• Competing OTC monograph products
• Private-label substitution
• Retailer sourcing changes
• Supplier qualification changes
• Trademark disputes
• Product-quality or labeling enforcement
• Patent disputes over a novel flavored or delivery format

The Orange Book is therefore not the primary source for ClearLax exclusivity analysis. FDA’s OTC monograph framework and product labeling are more relevant.[2,3]

What generic entry risks exist for ClearLax?

Generic and store-brand entry risk is high because the product has a simple formulation and an established active ingredient. A competitor can generally target the same consumer need with an equivalent PEG 3350 powder, provided the product complies with applicable FDA requirements.

The main risks are commercial rather than legal:

1. Retailer replacement by a lower-cost supplier.
2. Private-label price competition.
3. National-brand promotions.
4. Club-store bulk packaging.
5. E-commerce sellers offering lower unit costs.
6. Pharmacy benefit or reimbursement substitution.
7. Consumer migration to gummies, fiber products, or magnesium-based products.

A conventional powder has limited switching costs. Retailers can often change suppliers without requiring consumers to adopt a new administration method.

How strong is the ClearLax patent estate?

The patent estate for the standard product is weak to moderate depending on what is included in the analysis.

The core drug product has low patent strength. A new packaging system or flavored powder could create narrower protection, but those rights would cover specific embodiments rather than the entire PEG 3350 market.

Relative strength by asset

Asset	Patent strength	Business value
Standard PEG 3350 powder	Low	High as a low-cost commodity
Novel taste-masked powder	Moderate if technically differentiated	Moderate to high
Rapid-dissolution formulation	Moderate	Moderate
Moisture-barrier sachet	Low to moderate	Moderate
Child-friendly presentation	Low	Moderate
New indication	Low for routine constipation	Limited
Retail brand and trade dress	Moderate	High in private-label channels
Supplier and process know-how	Moderate as trade secret	High operational value

A patent filing should focus on measurable technical advantages, such as reduced dissolution time, improved stability, lower hygroscopicity, better content uniformity, or improved taste scores. Broad claims covering PEG 3350 plus ordinary flavoring agents would face validity and enforcement challenges.

What manufacturing and IP barriers affect ClearLax?

Manufacturing barriers are manageable but commercially important. PEG 3350 is sensitive to handling conditions that can influence flow, caking, dose uniformity, and packaging performance.

Key controls include:

• Qualified PEG 3350 suppliers
• Particle-size specifications
• Humidity-controlled blending and filling
• Accurate 17-gram dose control
• Moisture-resistant packaging
• Container-closure testing
• Stability testing under accelerated and long-term conditions
• Batch-to-batch sensory consistency for flavored products

Supplier qualification can become a meaningful competitive barrier if a company secures reliable pharmaceutical-grade PEG 3350 capacity at a lower cost. This is a supply-chain advantage, not a conventional exclusivity right.

What licensing deals could support ClearLax growth?

Licensing opportunities are more likely to involve capabilities than the PEG 3350 molecule. Relevant targets include:

• Flavor houses with gastrointestinal-tolerability expertise
• Stick-pack and sachet manufacturers
• Particle-engineering companies
• Contract manufacturers with OTC powder capacity
• Retailers seeking exclusive private-label variants
• E-commerce health platforms
• Senior-care and institutional distributors

A commercially useful agreement could provide exclusive rights to a flavor system, packaging configuration, or manufacturing process for a defined retail channel. A license limited to a specific formulation or geography would be more realistic than a broad PEG 3350 license.

How does ClearLax compare with MiraLAX and other laxatives?

Product category	Active ingredient	Formulation complexity	Patent barrier	Main commercial advantage
ClearLax	PEG 3350	Low	Low	Private-label price and pharmacy access
MiraLAX	PEG 3350	Low	Low for core product	National-brand recognition
Lactulose	Lactulose	Liquid	Low to moderate	Prescription and chronic-use positioning
Magnesium citrate	Magnesium citrate	Liquid	Low	Rapid consumer-perceived action
Senna products	Sennosides	Tablet, gummy, liquid	Low	Familiar stimulant-laxative category
Fiber products	Psyllium or other fiber	Powder, capsule, gummy	Variable	Daily digestive-health positioning

ClearLax is best positioned as a value product in a mature category. Its commercial upside depends on improving convenience or sensory acceptance without adding enough excipient or packaging cost to erase the private-label advantage.

What commercial opportunities are most attractive?

The strongest opportunities are:

1. Premium unit-dose sachets for travel and mail-order pharmacy.
2. Flavored versions with broad beverage compatibility.
3. Family-size and club packs for retail value channels.
4. Institutional packs for assisted living and post-discharge care.
5. E-commerce subscription bundles.
6. Retailer-exclusive variants with differentiated packaging.
7. Sustainable packaging, provided moisture protection remains adequate.
8. A pediatric-oriented presentation only if supported by appropriate labeling and clinical-regulatory analysis.

Product-line expansion should preserve the standard unflavored powder as the cost anchor. A premium variant can increase margin without forcing all consumers into a higher-cost format.

Public product-level revenue for Good Neighbor Pharmacy ClearLax is not generally reported separately. The relevant commercial exposure should therefore be assessed through unit volume, retail distribution, gross margin, private-label contract terms, and category share rather than brand-level public revenue.

Key Takeaways

• Good Neighbor Pharmacy ClearLax is a PEG 3350 OTC osmotic laxative with a simple powder formulation.
• The product’s competitive advantage is cost, pharmacy distribution, and private-label positioning.
• The core formulation has limited practical patent protection.
• Paragraph IV litigation, biosimilar competition, and conventional Orange Book exclusivity are not central risks.
• Flavoring, sweeteners, rapid-dissolution systems, sachets, and moisture-barrier packaging offer the main excipient and product-development opportunities.
• Packaging and retail-channel differentiation are likely to produce greater value than complex reformulation.
• A novel formulation could support narrow patents if it demonstrates measurable technical performance.
• Generic and store-brand substitution risk is high.
• The most attractive commercial path is a tiered portfolio: low-cost unflavored powder, premium flavored product, and convenient unit-dose packaging.

FAQs

Is Good Neighbor Pharmacy ClearLax the same as MiraLAX?

Both products use polyethylene glycol 3350 as the active ingredient, but inactive ingredients, packaging, manufacturing source, labeling details, and quality controls may differ by product.

Can ClearLax be reformulated with electrolytes?

Yes, but adding electrolytes would create a materially different product with new formulation, labeling, stability, safety, and regulatory requirements. It would no longer be a simple PEG 3350-only private-label product.

Can a flavored ClearLax product receive patent protection?

Potentially. Protection would depend on a technically differentiated and non-obvious flavor, excipient, particle, or stability system. Ordinary PEG 3350 plus conventional flavoring would likely provide limited patent strength.

Is ClearLax exposed to biosimilar competition?

No. PEG 3350 is a synthetic polymer drug substance, not a biologic. Biosimilar approval pathways do not apply.

What is the best commercial format for ClearLax?

A 17-gram unit-dose sachet or stick pack with neutral or lightly flavored powder is likely to offer the best balance of convenience, differentiation, and manufacturing feasibility. The standard bottle remains important for the lowest-cost retail segment.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Polyethylene glycol 3350 powder for solution labeling. https://dailymed.nlm.nih.gov/

2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 334: Laxative drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-334

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

4. U.S. Pharmacopeia. (2024). Polyethylene glycol 3350 monograph. In United States Pharmacopeia and National Formulary. United States Pharmacopeial Convention.